Avantor, Inc.

NYSE:AVTR

Medical - Instruments & Supplies

Healthcare
$15.37 +0.69%

+$0.07 today

Market cap
$10.41B
Beta
0.96
P/E (TTM)
-11.7
EPS (TTM)
-$0.81
52W Low $7.27High $15.93

Volume 5.94M

Average 9.44M

AVTR Debt Repayment

Cash used to repay borrowings during the period.

Avantor, Inc.NYSE: AVTR

Debt Repayment · Q2 FY2026 · quarter ended Jun 2026

Debt repayment growth accelerates

Q2 FY2026 debt repayment of $112.1M (cash outflow) rose 1548.5% year over year, ahead of the -50.6% change in trailing-twelve-month debt repayment. Sequentially, it rose 6.4% from the prior quarter. Over 3 fiscal years it compounded at -19.9% a year.

Context

  • Debt repayment amounted to 4.9% of revenue in FY2025, down 14.9 pp from a year earlier.
  • Debt repayment grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +1548.5% holds above the trailing-twelve-month pace of -50.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$112.1M+6.4% QoQ
Last fiscal yearDec 2025
-$318.7M-76.2% YoY
LTMJun 2026
-$498.1M-50.6% YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1548.5%——
1 year-76.2%——
3-year CAGR-19.9%——
5-year CAGR——
10-year CAGR——

Debt Repayment history

USD · from the cash flow

Latest · FY2025
(318.7M) USD
Year-over-year change
+76.2%

Debt Repayment vs competitors

How AVTR compares with its peers on the latest reported figures

  • Peers report in different currencies, so debt repayment is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -50.6% is the 7th highest of 9, against a peer median of +53.4%.
  • Debt repayment amounts to 7.6% of revenue for AVTR, versus a peer median of 1.1%.
AVTR Competitors
Debt Repayment for AVTR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DHRDanaher CorporationLTM Sep 2026$8.31B USD+3911.5%—32.4%
AVTRAvantor, Inc.LTM Jun 2026$498.1M USD-50.6%-19.9%7.6%
CRLCharles River Laboratories International, Inc.LTM Jun 2026$321.89M USD+456.1%—8.0%
STVNStevanato Group S.p.A.LTM Jun 2026€24.54M EUR-74.4%—2.0%
BLFSBioLife Solutions, Inc.LTM Mar 2026$10M USD+12.8%—10.0%
WSTWest Pharmaceutical Services, Inc.LTM Jun 2026$1.3M USD-68.3%-70.8%0.0%
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$900K USD+94.0%—0.0%
AZTAAzenta, Inc.LTM Sep 2026$748K USD-24.1%+9.0%0.1%
RGENRepligen CorporationLTM Jun 2026$0 USD+100.0%—0.0%
Peer median (excluding AVTR) —+53.4%-30.9%1.1%

Competitors are the stored peer set for AVTR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income572.6M686.5M321.1M711.5M(530.2M)
Depreciation & Amortization379.2M405.5M402.3M405.5M410.2M
Deferred Income Tax(17.7M)(69.1M)(172.4M)(46.9M)7.7M
Stock-Based Compensation50.7M45.8M40.5M46.8M46.4M
Change in Working Capital(114.5M)(321.3M)16.6M47.7M(198.9M)
Accounts Receivables(111.8M)(45.2M)77M45.9M13.6M
Inventory(129.8M)(112.5M)30.3M(18.5M)(109.4M)
Accounts Payables64.9M15.6M(139.6M)59.6M42.4M
Other Working Capital62.2M(179.2M)48.9M(39.3M)(145.5M)
Other Non-Cash Items83.3M96.2M261.9M(323.8M)888.6M
Operating Cash Flow953.6M843.6M870M840.8M623.8M
Capital Expenditures(111.1M)(133.4M)(146.4M)(148.8M)(128.8M)
Acquisitions (Net)(4.01B)(20.2M)000
Purchases of Investments00000
Sales of Investments042.5M000
Other Investing Activities3.5M1.5M2.7M587.7M(1.7M)
Investing Cash Flow(4.12B)(109.6M)(143.7M)438.9M(130.5M)
Debt Repayment2.3B(620.4M)(846M)(1.34B)(318.7M)
Common Stock Issued967M0005.1M
Common Stock Repurchased(25.8M)(13.2M)(13.7M)(8.6M)(80.7M)
Dividends Paid(64.6M)(32.4M)000
Other Financing Activities41.9M17.3M16M69.2M(15.1M)
Financing Cash Flow3.22B(648.7M)(843.7M)(1.28B)(409.4M)
Effect of Forex Changes(13.2M)(15.5M)8.2M(21.5M)19.7M
Net Change in Cash37.9M69.8M(109.2M)(23M)103.6M
Free Cash Flow842.5M710.2M723.6M692M495M

Avantor, Inc.

NYSE:AVTR

Intrinsic Alpha fair value

Locked

Current Price

$15.37

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.